Pelthos Therapeutics Inc. (PTHS)
NYSE: PTHS · Biological Products, (No Diagnostic Substances) · Durham, NC · filing with the SEC since 2022
Income statement, as filed
In US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
| Report filed | Mar 19, 2026 | Mar 27, 2025 | Apr 16, 2024 | · |
| Revenue | 16,795,000 | 0 | · | · |
| Cost of revenue | 3,988,000 | 0 | · | · |
| Research and development | 1,228,000 | 1,179,000r | 2,579,418 | 391,730 |
| Selling, general and administrative | 42,453,000 | 6,392,000 | · | · |
| General and administrative | · | 4,110,045 | 2,738,948 | 1,098,848 |
| Total operating expenses | · | 7,571,449 | 6,862,284 | 2,318,159 |
| Total costs and expenses | 49,225,000 | 7,571,000 | · | · |
| Operating income | -32,430,000 | -7,571,000r | -6,862,284 | -2,318,159 |
| Interest expense | 3,012,000 | 786,000 | 309,094r | 135,630 |
| Total non-operating income (expense) | -18,276,000 | -384,000r | -518,509 | -140,430 |
| Income before income taxes | -50,706,000 | -7,955,000 | -7,380,793 | -2,458,589 |
| Income tax expense | -7,387,000 | 0 | · | · |
| Net income | -43,319,000 | -7,955,000r | -7,380,793 | -2,458,589 |
| Earnings per share, basic | -23.04 | -14.27r | -57.80rb | 56.50b |
| Earnings per share, diluted | -23.04 | -14.27r | -57.80b | · |
| Weighted average shares, basic | 1,880,498 | 557,447r | 127,654b | 43,531b |
| Weighted average shares, diluted | 1,880,498 | 557,447r | 127,654b | · |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.Share counts and per-share figures are on the newest report's basis, after the 1-for-10 reverse split of Sep 2026.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTaxCost of revenue what it cost to make or buy what it sold
us-gaap:CostOfGoodsAndServicesSoldResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseSelling, general and administrative the cost of selling and of running the company
us-gaap:SellingGeneralAndAdministrativeExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesTotal costs and expenses every operating cost, the cost of revenue included
us-gaap:CostsAndExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseNonoperating
us-gaap:InterestExpenseDebtTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding